readthroughSign in
CompanyAUPHNasdaqEdmonton, A0

Aurinia Pharmaceuticals Inc.

Aurinia develops voclosporin, an oral calcineurin inhibitor approved for lupus nephritis, and aritinercept, a dual BAFF/APRIL inhibitor in development for autoimmune diseases.

424B3Nov 12Latest SEC filing
Oct 30Latest story